Review of preclinical data on hyperthermia treatment in lymphomas and its potential for clinical application.

Introduction: Hyperthermia (HT) at temperatures between 39 °C and 44 °C is utilized as an adjunctive cancer therapy, serving as potent radio- and chemosensitizer. Its effectiveness in treating solid malignancies has been well established. This raises the question of whether HT can also benefit patients with nonsolid tumors, such as lymphomas.

Comparisons of computer simulations and experimental data for capacitive hyperthermia using different split-phantoms.

Introduction: Several positive clinical trials have demonstrated that capacitive hyperthermia (CHT) improves the effectiveness of radiation therapy for the treatment of various cancer entities. However, the ability of CHT to induce significant heating throughout the body is under debate.

Objectives: To perform a pilot study involving comparisons of computer simulations and experimental data using different split-phantoms to validate hyperthermia treatment modeling for pre-planning for a clinical CHT system and to investigate the feasibility of split-phantom measurements in capacitive hyperthermia.